Surgical endoscopy

How pre-surgery treatment with GLP-1 drugs may affect weight loss after weight-loss surgery

Updated

Abstract

Among 323 diabetic patients undergoing bariatric surgery, 132 (40.9%) were on a GLP-1 receptor agonist at the time of their procedure.

  • GLP-1 receptor agonist naive patients were less likely to have high cholesterol compared to those on GLP-1RAs (57% vs 69%).
  • GLP-1 receptor agonist naive patients were more likely to undergo Roux-en-Y gastric bypass surgery than those on GLP-1RAs (84.82% vs 62.88%).
  • No differences were observed in 30-day postoperative outcomes between the two groups.
  • At one year post-surgery, GLP-1 receptor agonist naive patients experienced greater weight loss compared to patients on GLP-1RAs (24.1% vs 20.5%).
  • By five years post-surgery, weight loss between the groups was similar, with GLP-1 receptor agonist naive patients at 19.8% total body weight loss compared to 19.4% for those on GLP-1RAs.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declarations. Disclosures: Mr. Friesch, Mr. Fernando, Dr. Sheedy, Dr. Helenowski, Dr. Wool, Dr. Edwards, Dr. Brown, Dr. Lau, and Dr. Cohn have no conflict of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free